Pipeline
COBIK is aimed to address the most pressing health challenges of the 21st century: antibiotic resistance and emerging viral diseases. Our pipeline is focused on bacteriophage-based solutions and viral vaccines.
We are developing potent antibacterial therapy and nanoparticle vaccine candidate pipeline by applying state-of-the-art bioengineering, genetic and molecular biology tools. Together, we deliver a broad spectrum of next generation therapeutics to combat the emerging threats of infectious disease.
Antibacterials
| Name | Target | Stage development pre-clinical clinical trial |
|---|---|---|
| COP-01/20 | multidrug-resistant S. epidermidis | development |
| The powerful broad-spectrum phage COP-01/20 cocktail was developed to treat multidrug-resistant Staphylococcus epidermidis infections. Careful COP-01/20 phage selection and purification process provide excellent efficiency and safety profile. | ||
Vaccines
| Name | Target | Stage development pre-clinical clinical trial |
|---|---|---|
| CO-CoVac-01 | SARS CoV-2 | development |
| We developed the CO-CoVac-01 vaccine candidate against COVID-19 by using an innovative nanoparticle-based platform. CO-CoVac-01 mimics SARS-CoV-2 particles to deliver safe and robust protection. | ||
